NMTRQ — 9 Meters Biopharma Share News
0.000.00%
Last trade - 00:00FinancialsHighly SpeculativeMicro Cap
9 Meters Biopharma Inc reports results for the quarter ended in December - Earnings Summary
U.S. RESEARCH ROUNDUP-Amazon.com, Dell, Unum Group, Penumbra
U.S. RESEARCH ROUNDUP-Amazon.Com, Unum Group, Penumbra
9 Meters Biopharma Inc expected to post a loss of 82 cents a share - Earnings Preview
Brief: 9 Meters Biopharma Inc Says Does Not Hold Any Deposits Or Securities Or Maintain Any Accounts At Silicon Valley Bank
U.S. RESEARCH ROUNDUP-Apollo Global Management, First American Financial, Thomson Reuters
U.S. STOCKS ON THE MOVE-Ralph Lauren, J.M. Smucker, Lions Gate
U.S. STOCKS ON THE MOVE-Silvergate Capital, PayPal, Spotify
U.S. STOCKS ON THE MOVE-Cloudflare, Coursera, Corsair Gaming
Citi initiates coverage on 9 Meters Biopharma with 'neutral'
Brief: 9 Meters Biopharma Says On January 12, Co And Holder Agreed To Amend The A&R Note
Brief: 9 Meters Biopharma Inc - 9 Meters Biopharma Announces Phase 3 Study Of Vurolenatide In Short Bowel Syndrome
U.S. RESEARCH ROUNDUP- Boeing, Intel, Silvergate Capital
U.S. RESEARCH ROUNDUP-Charter Communications, Guild Holdings, Waste Management
9 Meters gains as short bowel syndrome drug succeeds in mid-stage study
Brief: 9 Meters Biopharma Inc Reports Cash Balance As Of June 30, 2022 Of $29.5 Million
Brief: 9 Meters Biopharma Files Prospectus Relates To Possible Resale Of Up To 144.6 Million Shares Of Common Stock From Time To Time By Selling Stockholders
Brief: 9 Meters Biopharma Entered Into Securities Purchase Agreement For Purchase Of Senior Secured Convertible Notes With Institutional Investor
Brief: 9 Meters Biopharma Announces Preliminary Results From Phase 2 Study Of Vurolenatide In Short Bowel Syndrome